• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Andrew Left Takes Long Stance on Valeant, Awaiting 'Bounce' in Shares

The same activist short seller who helped drive Valeant shares down last fall appears to be changing strategy.
By JAMES PASSERI May 16, 2016 | 02:42 PM EDT
Stocks quotes in this article: VRX

It appears Citron Research's Andrew Left is changing tack on beleagured Canadian drugmaker Valeant Pharmaceuticals (VRX).

The activist short seller -- who helped send shares of Valeant into a tailspin last fall -- said in a Monday interview with Real Money that he "wouldn't be surprised if there's a bounce" in the drugmaker's stock, which has fallen more than 90% since last summer. 

"I'm long for Valeant, but I also own some out-of-the-money puts," he said, noting he's unfazed by Valeant's decision today to broaden discounts on two drugs, Nitropress and Isuprel. (Puts are common investment vehicles used in short selling.) "I don't think they're going to make any decisions that are going to torpedo their company," Left added.

The most important metric in gauging Valeant's recovery, according to Left, will be sales of its flagship Xifaxan, which was obtained as part of Valeant's $11 billion acquisition of Salix last April. Robust sales will be crucial to spur growth, especially as Valeant looks to offload a roughly $31 billion debt burden, Left added.

Valeant has long been trying to extricate itself from intense media scrutiny surrounding allegations that the company has unfairly hiked drug prices to exorbitant levels, with its former CEO, Michael Pearson, appearing before the Senate Special Committee on Aging last month to apologize for having said shareholder interests were his top priority, interests above patient and hospital concerns.

On Monday, its new CEO, Joseph Papa, reiterated his mission to rebrand the company's image as a patient-first drugmaker, as part of his broadening of product discounts.

"I also want to thank the Senate Committee on Aging and the House Committee on Oversight and Government Reform for the attention they have brought to this issue, and specifically to gaps they identified in the previous program," he said in a Monday statement. "We are committed to getting this right."

 -- Real Money's Carleton English contributed to this report.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Boston Scientific's Wicked Rally Can Take the Stock 20% Higher

Bruce Kamich
Mar 21, 2023 2:59 PM EDT

BSX has rallied the past nine months.

Why Weakness in Sarepta Therapeutics Is Likely to Continue

Bruce Kamich
Mar 17, 2023 1:20 PM EDT

The trading days between the gaps look like an island surrounded by water.

When Will AbbVie's Long-Term Trend Reassert Itself?

Bruce Kamich
Mar 17, 2023 9:28 AM EDT

Let's drill down on the charts.

3 High Dividend Healthcare Stocks for Passive Income

Bob Ciura
Mar 11, 2023 7:15 AM EST

These recession-resilient names offer above-average dividend yields and decent growth prospects.

Here's How Innovation Can Drive Apple Higher

Ed Ponsi
Mar 7, 2023 10:30 AM EST

The tech giant's stock won a buy rating from Goldman Sachs, and its work on a medical innovation could be a game-changer.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login